Stockscreener 앱 받기
16.44
0.93%
-0.155
시간 외 거래:
16.44
전일 마감가:
$16.59
열려 있는:
$16.6
하루 거래량:
740.88K
Relative Volume:
0.59
시가총액:
$2.19B
수익:
$298.30M
순이익/손실:
$298.21M
주가수익비율:
7.5981
EPS:
2.1637
순현금흐름:
$166.93M
1주 성능:
-2.72%
1개월 성능:
-1.85%
6개월 성능:
+14.41%
1년 성능:
+27.94%
1일 변동 폭
$16.31
$16.78
1주일 범위
$16.27
$16.91
52주 변동 폭
$10.34
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.44 | 2.19B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
Discipline and Rules-Based Execution in AUPH Response - Stock Traders Daily
A look at a few stocks - Moomoo
Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside (AUPH) - Seeking Alpha
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurora Innovation stock reacts as Uber cuts its stake and Aurinia delivers strong Q2 figures - AD HOC NEWS
Aurinia Stock Jumps After Earnings Beat And Pipeline Progress - simplywall.st
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company - Yahoo Finance
Technical Reactions to AUPH Trends in Macro Strategies - Stock Traders Daily
Aurinia Pharmaceuticals (NASDAQ: AUPH) Chief Legal Officer Stephen P. Robertson Disposes 11,939 Shares at $15.95 on September 10, 2026 - kalkinemedia.com
Aurinia Pharmaceuticals' Chief Legal Officer Sells 11,939 Shares to Cover Tax Withholding on PSU Vesting - Kalkine Media
Tax-withholding stock sale by Aurinia Pharmaceuticals (AUPH) legal chief - Stock Titan
GOOGL Stock Price TodayAlphabet Inc Class A News, Charts, Retail Sentiment - Stocktwits
Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH? - StockInvest.us
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
LB Pharmaceuticals Names Joseph M. Miller as CFO, Details Compensation and Severance Package - kalkinemedia.com
LB Pharmaceuticals Inc Announces Appointment of Joseph M. Miller to Chief Financial Officer, Effective September 2, 2026 - marketscreener.com
A finance executive who helped launch a lupus drug joins LB Pharmaceuticals - Stock Titan
Is Aurinia Pharmaceuticals (AUPH) Still Below Fair Value After A 60% Rise? - simplywall.st
Kezar Life Sciences stock in focus after Aurinia tender offer and merger terms surface - AD HOC NEWS
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)? - Yahoo Finance
InMed Pharmaceuticals Inc. (INM) Peer Comparison – Compare with Others - Value Research
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock - Benzinga
ILJIN group pushes Aurinia (NASDAQ: AUPH) stake under 5% after share sales - Stock Titan
Aurinia (NASDAQ: AUPH) legal chief sells shares to cover taxes - stocktitan.net
Aurinia (AUPH) Quarterly Results: EPS Clears the Reported Estimate at the Close; Market Response: The Share Price Sheds 0.48% in the Available RecordGuidance Update - vinanet.vn
Aurinia (AUPH) Market: Falls 3.59% to $16.65 at the Close; Technical Setup: $15.82 and $17.48 Define the Nearby Reference Levels on the DayBuyback Factor - siam.in
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
AUPH Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - Stocktwits
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia settles patent dispute with Teva over generic drug By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Australia
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Aurinia Settles Patent Litigation with Teva - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):